Tumor therapeutics in the era of “RECIST”: past, current insights, and future prospects

Zhilong Xu, Gening Jiang, Jie Dai
ISSN / E-ISSN
— / —
DOI
10.3389/or.2024.1435922 ↗
Volume · Issue · Pages
18 · — · 1435922-1435922
Publisher
PagePress Publications
Article URL
https://doi.org/10.3389/or.2024.1435922 ↗
Article details
Unverified
Publication date (each date has its type and source)
18 Oct 2024
OpenAlex publication date · source: OpenAlex
Dates on record for this article
TypeDateSource
OpenAlex publication date18 Oct 2024 OpenAlex

Keywords (as given): RECIST; tumor response assessment; response evaluation criteria; pseudoprogression; immune checkpoint inhibitors; neoadjuvant therapy; advanced imaging; treatment efficacy assessment

HEC Status at Publication Not the journal's current status

HEC Status at PublicationNot conclusive
Best available information, not a definitive status: Some rows of the HEC list for this period are not yet matched to a journal, so absence cannot be proved. Pending verification.
Journal
Oncology Reviews
Publication date used
18 Oct 2024 (OpenAlex publication date)
Applicable HEC period
2024–25 (version 1) · 01 Oct 2024 – 31 Mar 2026
Category
—
Recognition status
Pending Verification (PERIOD_HAS_UNMATCHED_ROWS)
Source
—
Verification status
Unverified
This is an automatically generated summary based on the information available on the publication date. Terms & conditions apply.